An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
Abstract Background We present the study rationale and design of the JGOG3023 study, an open-label, parallel-arm, randomized, phase II trial that aimed to assess the efficacy and safety of chemotherapy with or without bevacizumab in patients with platinum-resistant recurrent epithelial ovarian, fall...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-018-4505-4 |
| _version_ | 1828531677739089920 |
|---|---|
| author | Tadahiro Shoji Shinichi Komiyama Junzo Kigawa Hiroshi Tanabe Kazuyoshi Kato Hiroaki Itamochi Hiroyuki Fujiwara Shoji Kamiura Tetsutaro Hamano Toru Sugiyama for the Japanese Gynecologic Oncology Group |
| author_facet | Tadahiro Shoji Shinichi Komiyama Junzo Kigawa Hiroshi Tanabe Kazuyoshi Kato Hiroaki Itamochi Hiroyuki Fujiwara Shoji Kamiura Tetsutaro Hamano Toru Sugiyama for the Japanese Gynecologic Oncology Group |
| author_sort | Tadahiro Shoji |
| collection | DOAJ |
| description | Abstract Background We present the study rationale and design of the JGOG3023 study, an open-label, parallel-arm, randomized, phase II trial that aimed to assess the efficacy and safety of chemotherapy with or without bevacizumab in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer. We hypothesize that patients treated with a combination of single-agent chemotherapy and bevacizumab will show improved progression-free survival (PFS) compared with those treated with single-agent chemotherapy alone, in the setting beyond disease progression following prior bevacizumab treatment. Methods/design A total of 106 patients who have recurrence or progression of ovarian cancer, while receiving chemotherapy or within 6 months after the final dose of platinum, after completing at least three cycles of bevacizumab plus platinum chemotherapy will be randomized in a 1:1 ratio to treatment with single-agent chemotherapy or single-agent chemotherapy combined with bevacizumab. For chemotherapy, one of the following four drugs will be chosen by an investigator: pegylated liposomal doxorubicin, topotecan, paclitaxel, or gemcitabine. The primary endpoint is investigator-assessed PFS. The secondary endpoints are overall survival, objective response rate, number of paracentesis, and response rate by CA125. Safety will be evaluated by the incidence of adverse events. Discussion This study will assess the efficacy and safety of bevacizumab in combination with single-agent chemotherapy, which could be used continuously after disease progression following standard platinum-based chemotherapy with bevacizumab. Trial registration UMIN000017247 (registered April 22, 2015). |
| first_indexed | 2024-12-11T22:41:16Z |
| format | Article |
| id | doaj.art-50718e1a031a4176b1c4e284b599417a |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-11T22:41:16Z |
| publishDate | 2018-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-50718e1a031a4176b1c4e284b599417a2022-12-22T00:47:47ZengBMCBMC Cancer1471-24072018-07-011811810.1186/s12885-018-4505-4An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023Tadahiro Shoji0Shinichi Komiyama1Junzo Kigawa2Hiroshi Tanabe3Kazuyoshi Kato4Hiroaki Itamochi5Hiroyuki Fujiwara6Shoji Kamiura7Tetsutaro Hamano8Toru Sugiyama9for the Japanese Gynecologic Oncology GroupDepartment of Obstetrics and Gynecology, Iwate Medical University School of MedicineDepartment of Gynecology, Toho University Ohashi Medical CenterDepartment of Obstetrics and Gynecology, Matsue City HospitalDepartment of Obstetrics and Gynecology, The Jikei University School of Medicine, Kashiwa HospitalDepartment of Gynecology, Cancer Institute HospitalDepartment of Obstetrics and Gynecology, Iwate Medical University School of MedicineDepartment of Obstetrics and Gynecology, Jichi Medical UniversityDepartment of Gynecology, Osaka Medical Center for Cancer and Cardiovascular DiseasesClinical Trial Coordinating Center, Kitasato Academic Research Organization, Kitasato UniversityDepartment of Obstetrics and Gynecology, Iwate Medical University School of MedicineAbstract Background We present the study rationale and design of the JGOG3023 study, an open-label, parallel-arm, randomized, phase II trial that aimed to assess the efficacy and safety of chemotherapy with or without bevacizumab in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer. We hypothesize that patients treated with a combination of single-agent chemotherapy and bevacizumab will show improved progression-free survival (PFS) compared with those treated with single-agent chemotherapy alone, in the setting beyond disease progression following prior bevacizumab treatment. Methods/design A total of 106 patients who have recurrence or progression of ovarian cancer, while receiving chemotherapy or within 6 months after the final dose of platinum, after completing at least three cycles of bevacizumab plus platinum chemotherapy will be randomized in a 1:1 ratio to treatment with single-agent chemotherapy or single-agent chemotherapy combined with bevacizumab. For chemotherapy, one of the following four drugs will be chosen by an investigator: pegylated liposomal doxorubicin, topotecan, paclitaxel, or gemcitabine. The primary endpoint is investigator-assessed PFS. The secondary endpoints are overall survival, objective response rate, number of paracentesis, and response rate by CA125. Safety will be evaluated by the incidence of adverse events. Discussion This study will assess the efficacy and safety of bevacizumab in combination with single-agent chemotherapy, which could be used continuously after disease progression following standard platinum-based chemotherapy with bevacizumab. Trial registration UMIN000017247 (registered April 22, 2015).http://link.springer.com/article/10.1186/s12885-018-4505-4BevacizumabPlatinum-resistant ovarian cancerOvarian cancerChemotherapyProgression-free survivalBeyond progression |
| spellingShingle | Tadahiro Shoji Shinichi Komiyama Junzo Kigawa Hiroshi Tanabe Kazuyoshi Kato Hiroaki Itamochi Hiroyuki Fujiwara Shoji Kamiura Tetsutaro Hamano Toru Sugiyama for the Japanese Gynecologic Oncology Group An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 BMC Cancer Bevacizumab Platinum-resistant ovarian cancer Ovarian cancer Chemotherapy Progression-free survival Beyond progression |
| title | An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 |
| title_full | An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 |
| title_fullStr | An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 |
| title_full_unstemmed | An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 |
| title_short | An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 |
| title_sort | open label randomized phase ii trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum resistant epithelial ovarian fallopian tube or primary peritoneal cancer patients previously treated with bevacizumab for front line or platinum sensitive ovarian cancer rationale design and methods of the japanese gynecologic oncology group study jgog3023 |
| topic | Bevacizumab Platinum-resistant ovarian cancer Ovarian cancer Chemotherapy Progression-free survival Beyond progression |
| url | http://link.springer.com/article/10.1186/s12885-018-4505-4 |
| work_keys_str_mv | AT tadahiroshoji anopenlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarian AT shinichikomiyama anopenlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarian AT junzokigawa anopenlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarian AT hiroshitanabe anopenlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarian AT kazuyoshikato anopenlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarian AT hiroakiitamochi anopenlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarian AT hiroyukifujiwara anopenlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarian AT shojikamiura anopenlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarian AT tetsutarohamano anopenlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarian AT torusugiyama anopenlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarian AT forthejapanesegynecologiconcologygroup anopenlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarian AT tadahiroshoji openlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarianca AT shinichikomiyama openlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarianca AT junzokigawa openlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarianca AT hiroshitanabe openlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarianca AT kazuyoshikato openlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarianca AT hiroakiitamochi openlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarianca AT hiroyukifujiwara openlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarianca AT shojikamiura openlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarianca AT tetsutarohamano openlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarianca AT torusugiyama openlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarianca AT forthejapanesegynecologiconcologygroup openlabelrandomizedphaseiitrialevaluatingtheefficacyandsafetyofstandardofcarewithorwithoutbevacizumabinplatinumresistantepithelialovarianfallopiantubeorprimaryperitonealcancerpatientspreviouslytreatedwithbevacizumabforfrontlineorplatinumsensitiveovarianca |